DYSLIPIDEMIA AND CARDIOVASCULAR RISK STRATIFICATION
DOI:
https://doi.org/10.63330/aurumpub.024-028Keywords:
Dyslipidemia, Cardiovascular risk, LDL-cholesterol, Atherosclerosis, Cardiovascular preventionAbstract
Dyslipidemia is one of the main modifiable risk factors for the development of cardiovascular diseases (CVD), responsible for high morbidity and mortality worldwide. It is characterized by quantitative and qualitative changes in plasma lipids, including an increase in total cholesterol, low-density lipoprotein cholesterol (LDL-cholesterol), triglycerides and/or a reduction in high-density lipoprotein cholesterol (HDL-cholesterol). Correct cardiovascular risk stratification is essential to individualize the therapeutic approach, define lipid goals and reduce major cardiovascular events. This article reviews the pathophysiological concepts of dyslipidemia, its classifications, diagnostic methods and the main cardiovascular risk stratification models, with emphasis on current guidelines.
Downloads
References
1. MACH, F.; BAIGER, L.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, v. 41, p. 111–188, 2019.
2. GRUNDY, S. M.; STONE, N. J.; et al. 2018 Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019 (errata/online 2018). v. —, 2018/2019.
3. FALUDI, A. A.; et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose — Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arquivos Brasileiros de Cardiologia, suplemento, 2017.
4. CHOLESTEROL TREATMENT TRIALISTS’ (CTT) COLLABORATION. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of individual data from randomised trials. Lancet, 2010. (CTT meta-analysis).
5. CHOLESTEROL TREATMENT TRIALISTS’ (CTT) COLLABORATION. The effects of lowering LDL cholesterol with statin therapy in different patient groups: meta-analysis. Lancet, 2012.
6. CONROY, R. M.; PYORALA, K.; et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal, v. 24, n. 11, p. 987–1003, 2003.
7. WILSON, P. W. F.; et al. Prediction of coronary heart disease using risk factor categories. Circulation, v. 97, n. 18, p. 1837–1847, 1998. (Framingham risk function).
8. SCORE2-OP / ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease (SCORE2, 2021). European Heart Journal, 2021.
9. GOFF, D. C. Jr.; et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: Pooled Cohort Equations and risk estimation. Circulation, 2014.
10. CESENA, F. H. Y.; et al. Cardiovascular risk stratification and statin eligibility: discussão sobre escores e estratificação. Arquivos Brasileiros de Cardiologia, v. 108, n. 6, p. 508–519, 2017.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
